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2830Objectives: The logistic European System for Cardiac Operative Risk Evaluation (LES) score and the Society
of Thoracic Surgeons (STS) score are validated to predict 30-day outcomes following surgical aortic valve
replacement (SAVR) with or without coronary artery bypass grafting. Their performance when applied to
patients undergoing transcatheter aortic valve replacement (TAVR) is controversial.
Methods:We compared predicted and observed 30-day/in-hospital and 1-year mortality of patients undergoing
TAVR in the first Placement of Aortic Transcatheter Valves trial and continued access registry (N ¼ 2466). The
performance of the LES and STS scores (prospectively calculated) was evaluated using standard assessments of
discrimination and calibration. Performance of STS and LES scores among 307 patients undergoing SAVR from
the high-risk cohort of the randomized trial were also examined.
Results: In patients undergoing TAVR, the observed 30-day/in-hospital mortality was 6.5%, whereas the
predicted 30-day mortality was higher by both STS score (11.4%  3.9%) and LES score (26.6% 
16.2%). The discrimination for both scores was poor for 30-day/in-hospital and 1-year mortality. Calibration
was better for STS score than for LES at 1 year but poor for both at 30 days among TAVR cohort. These
results were consistent among the subgroups of patients undergoing transfemoral and transapical access;
however, the STS score had better performance among the high-risk patients who underwent SAVR at 30
days but not 1 year.
Conclusions: The STS and LES surgical risk scores overestimated 30-day/in-hospital mortality and were poor
discriminators of post-TAVRmortality, but the calibration of the STS scorewas better in these high-risk patients.
These data highlight the need for TAVR-specific risk models to optimize patient selection. (J Thorac Cardiovasc
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AS ¼ aortic stenosis
LES ¼ logistic European System for Cardiac
Operative Risk Evaluation
PARTNER ¼ Placement of Aortic Transcatheter
Valve trial
STS ¼ Society of Thoracic Surgeons
SAVR ¼ surgical aortic valve replacement
TAVR ¼ transcatheter aortic valve replacement
TA ¼ transapical
TF ¼ transfemoral
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DPatients considered for transcatheter aortic valve replace-
ment (TAVR) for severe symptomatic aortic stenosis
(AS) are frequently elderly, frail, and have multiple
comorbidities.1,2 These comorbidities, individually or in
combination, are associated with increased perioperative
morbidity and mortality as well as diminished late
survival. The Placement of Aortic Transcatheter Valve
trials (PARTNER I and PARTNER II) demonstrated that
TAVR decreased mortality on an absolute scale by 20%
compared with standard therapy among patients with
severe AS deemed unsuitable for surgical aortic valve
replacement2,3 (SAVR) and was associated with similar
rates of survival compared with SAVR among high-risk pa-
tients at 1, 2, and 3 years of follow-up.1,4 Despite these
encouraging results, overall mortality following TAVR in
high-risk patients is high (44.2% at 3 years).5 Thus, accurate
prediction of procedural and subsequent outcomes is critical
to inform decisions as patients are considered for TAVR.
The logistic European System for Cardiac Operative Risk
Evaluation (LES) score and the Society of Thoracic Sur-
geons (STS) predicted risk of mortality score are validated
risk scores predicting 30-day outcomes in patients undergo-
ing SAVR with or without coronary artery bypass graft-
ing.6,7 Both the STS score and the LES score accurately
predict mortality in low-risk patients undergoing bypass
surgery but have not been well validated in high-risk pa-
tients undergoing SAVR.8 Similarly, neither the STS score
nor the LES algorithm was designed to predict outcomes
among patients undergoing TAVR. Notwithstanding the
absence of prospective validation of these scores, the calcu-
lation of surgical risk scores has become widely integrated
into the evaluation of potential TAVR patients and is even a
prerequisite for risk assessment mandated by both the US
Food and Drug Administration and the Centers for Medi-
care and Medicaid Services.The Journal of Thoracic and CarIn our analysis, we sought to study the performance char-
acteristics of the STS and LES surgical risk scores at 30
days and 1 year among patients undergoing TAVR and
SAVR in the PARTNER I randomized and continued access
cohorts. While acknowledging that both the STS score and
LES score were designed to predict 30-day outcomes we
wanted to additionally test if baseline STS and LES surgical
risk scores could also be predictive of 1-year all-cause
observed mortality.
Specifically we hypothesized that both the STS and LES
surgical risk scores would show poor calibration and
discrimination regarding 30-day and 1-year all-cause
mortality when applied to high-risk patients with severe
AS undergoing TAVR or SAVR in the PARNTER I random-
ized and continued access cohorts.METHODS
Study Cohort
In this as-treated analysis of the PARTNER I trial, we combined the
randomized and continued access cohorts from the PARTNER I high-
risk (cohort A) and inoperable (cohort B) trials to provide a cumulative
population of 2552 TAVR patients and 313 SAVR patients. The PARTNER
trial design has been previously described and published.1,2 Briefly, the
PARTNER I trial enrolled patients with severe symptomatic AS (aortic
valve area 0.8 cm2 plus a peak velocity 4 mps or a mean transaortic
valve gradient 40 mm Hg). Patients were divided into 2 cohorts: those
who were considered to be candidates for surgery despite the fact that
they were at high surgical risk, as defined by an elevated STS risk score
or by the presence of coexisting conditions that would be associated
with a predicted risk of death by 30 days after surgery of at least 15%
(cohort A); and those who were not considered to be suitable candidates
for surgery because they had coexisting conditions that would be
associated with a predicted probability of 50% or more of either death
by 30 days after surgery or a serious irreversible condition (cohort B).
Patients from cohort B with a suitable iliofemoral vessel were
randomized to transfemoral (TF) TAVR with the Edwards-Sapien heart
valve system (Edwards Lifesciences, Irvine, Calif) or to standard
medical care. Patients enrolled in cohort A were randomized to TAVR
(TF if iliofemoral vessels were suitable or transapical [TA] TAVR if not)
or to conventional SAVR. The institutional review board at each partici-
pating site approved the study and all patients provided written informed
consent.
Study Outcomes
The clinical outcomes analyzed included observed 30-day/in-hospital
and 1-year all-cause mortality. The observed mortality was defined as adju-
dicated 30-day/in-hospital (all-cause mortality within 30 days of the index
procedure or during the index hospitalization) and 1-year all-cause mortal-
ity following the index TAVR or SAVR procedure. An independent clinical
events committee adjudicated all clinical events.
Statistical Analysis
Continuous variables are presented asmean (1 standard deviation) and
compared by Student t test or presented as median (interquartile range) and
compared by Mann-Whitney U test. Categorical variables are presented as
frequencies and percentages and compared by c2 test.
The LES score and STS predicted mortality score were prospectively
calculated with online calculators (http://www.euroscore.org; data set:
2.61, http://www.riskcalc.sts.org) by study investigators at participating
sites and integrated into a central database. The relationship betweendiovascular Surgery c Volume 148, Number 6 2831
FIGURE 1. Flow of participants in transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) cohorts. STS, Society of
Thoracic Surgeons; LES, logistic European System for Cardiac Operative Risk Evaluation.
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DLES and STS scores was quantified using Pearson correlation coefficient
and linear regression analysis.
The performance of the LES and STS risk algorithms were evaluated in
terms of their discrimination and calibration. Model discrimination was as-
sessed using the area under the receiver operating characteristic (AUC)
curve, analogous to the c statistic, with 95% confidence intervals. An
AUC of 0.5 indicates no discriminatory ability, whereas an AUC of 1.0 rep-
resents perfect discrimination.9,10 To assess calibration, observed and
predicted probabilities were graphically represented by a calibration plot.
A smooth line was fitted and the calibration slope and intercept were
reported. Perfect calibration was shown as a dashed line (Y ¼ X [45]
line, slope ¼ 1, intercept ¼ 0). Analyses of the performance
characteristics of LES and STS scores when applied separately to
patients undergoing TA and TF TAVR, cohort A (high-risk) and cohort B
(inoperable) as well as those patients undergoing SAVR, were
conducted. All statistical analyses were performed with SAS version 9.2
(SAS Institute Inc, Cary, NC).RESULTS
A total of 2552 high-risk and inoperable patients under-
went TAVR in cohort A (n ¼ 344) and B (n ¼ 175) of the
randomized and continued access (n ¼ 2033) PARTNER
trials. Of these, STS score was missing for 7 patients and
LES score was missing for 77 patients, resulting in a final
cohort of 2466 patients included in this analysis; of 313 pa-
tients whowere randomized to SAVR in cohort A of the ran-
domized PARTNER trial 6 had missing LES data, which
resulted in a final cohort of 307 patients whowere also eval-
uated (Figure 1). The majority of patients were octogenar-
ians, with an equal distribution of men and women
undergoing TAVR, but a there was higher prevalence of
men in the SAVR group. The majority of patients undergo-
ing TAVR or SAVR had an STS score>10%. Cardiovascu-
lar risk factors, cardiovascular conditions, and noncardiac
conditions are detailed for both the TAVR and SAVR pop-
ulations in Table 1.
Among patients undergoing TAVR, there were 165 of
2552 (6.5%) 30-day/in-hospital deaths. Of these, 111 of
2552 (4.3%) were adjudicated as due to cardiovascular2832 The Journal of Thoracic and Cardiovascular Surcauses. At 1 year, all-cause mortality was 21.3% with
9.5% of deaths adjudicated as due to cardiovascular causes.
Among 313 patients randomized to SAVR, there were 33
30-day/in-hospital deaths (10.5%), of which 11 (3.5%)
were adjudicated as due to cardiovascular causes. At 1
year, all-cause mortality was 25.2% with 7.6% of deaths
adjudicated as due to cardiovascular causes.Risk Score Performance Characteristics of Patients
Undergoing TAVR (n ¼ 2552)
The mean LES score was more than 2 times higher than
the mean STS score (26.6%  6.2% vs 11.4%  3.8%).
The observed 30-day/in-hospital mortality was 6.5%;
thus, the observed to predicted mortality ratio was 0.15
for the LES score and 0.57 for the STS score. There was a
weak (Y ¼ 0.0828x þ 9.1463; R ¼ 0.3405; r2 ¼ 0.12) rela-
tionship between the LES and STS scores.
Although the discrimination of STS score was better than
LES score (P ¼ .024), both were poor discriminators of
30-day/in-hospital outcomes (Table 2). When TA and TF
access patients were analyzed separately, the 30-day
discrimination for both STS score and LES score remained
poor for both TA (LES AUC ¼ 0.54 [95% CI, 0.48-0.60],
STS score AUC ¼ 0.59 [95% CI, 0.53-0.66]; P ¼ .23)
and TF (LES AUC ¼ 0.51 [95% CI, 0.44-0.58], STS score
AUC ¼ 0.58 [95% CI, 0.49-0.66]; P ¼ .32). No material
difference in performance when stratified by enrollment
cohort (high risk [cohort A] or inoperable [cohort B]) was
noted. At 1 year, discrimination of both scores remained
poor (Table 2).
Both risk scores demonstrated significant differences be-
tween predicted and observed mortalities throughout the
range of mortality risk when analyzed at the 30-day/in-hos-
pital time point (Table 3 and Figure 2, A and B). The
predictive performance of both risk scores remained
poor in the lower, mid, and high score predicted riskgery c December 2014
TABLE 1. Baseline characteristics of the study population
All TAVR
(cohort AþBþCA) (n ¼ 2552) SAVR (cohort A) (n ¼ 313)
Age, y 85.64 (80.81-89.28) 84.94 (80.77-88.72)
Age  80 y 78.5% (1989/2534) 79.2% (248/313)
Male 52.4% (1336/2550) 57.2% (179/313)
Body mass index 25.74 (22.620-29.64) 25.69 (23.04-29.52)
Society of Thoracic Surgeons score 11.43  3.83 (2543) 11.70  3.37 (313)
Logistic European System for Cardiac Operative Risk Evaluation score 26.55  16.25 (2468) 29.22  15.13 (307)
Cardiovascular risk factors
Any diabetes 37.2% (949/2550) 41.5% (130/313)
Hyperlipidemia 83.7% (2134/2550) 84.0% (263/313)
Smoking 48.4% (1233/2550) 49.8% (156/313)
Hypertension 91.8% (2340/2549) 93.9% (294/313)
Cardiovascular conditions
New York Heart Association functional class III-IV 94.7% (2413/2548) 94.9% (297/313)
Coronary artery disease 77.8% (1982/2549) 77.0% (241/313)
Prior myocardial infarction 26.0% (660/2536) 29.0% (90/310)
Prior percutaneous coronary intervention 39.8% (1013/2546) 32.4% (101/312)
Prior coronary artery bypass graft 42.7% (1088/2549) 44.7% (140/313)
Cerebrovascular disease 26.3% (656/2499) 27.1% (79/292)
Peripheral vascular disease 42.8% (1078/2520) 43.0% (132/307)
Prior balloon aortic valvuloplasty 23.3% (592/2538) 10.2% (32/313)
Pulmonary hypertension 38.9% (942/2419) 35.4% (95/268)
Major arrhythmia 50.5% (1286/2548) 51.3% (160/312)
Noncardiac conditions
Coagulopathy 2.3% (58/2542) 3.2% (10/312)
Renal disease 16.6% (423/2548) 19.5% (61/313)
Liver disease 2.7% (68/2546) 2.9% (9/313)
Chronic obstructive pulmonary disease 43.4% (1108/2552) 44.1% (138/313)
Values are presented as median (interquarile range), % (n), or mean  standard deviation (n). SAVR, Surgical aortic valve replacement; TAVR, transcatheter aortic valve
replacement; CA, continued access.
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the subgroups of patients undergoing TF and TA access.
At 1 year, the calibration was better with STS score
compared with LES score for the overall TAVR group
(Table 3 and Figure 2, E and F).
Risk Score Performance Characteristics of Patients
Undergoing SAVR (n ¼ 313)
Even among this surgical cohort, the mean LES score
was 3 times higher than the mean STS score (29.2% 
15.2% vs 11.7%  3.4%), and as such, the observed/pre-
dicted 30-day mortality ratio was 0.35 for the LES scoreTABLE 2. Receiver operating characteristics of Society of Thoracic Surg
Evaluation (LES) surgical risk scores
Original
validation
cohorts
Transcatheter aortic valve repla
30-day/in-hospital mortality
STS score 0.78 0.60 (0.55-0.65)
LES score 0.76 0.53 (0.48-0.57)
P value (STS score vs LES) .024
Values are presented as area under the receiver operating characteristic curve (95% confid
Cardiac Operative Risk Evaluation.
The Journal of Thoracic and Carand 0.89 for the STS score. There was a weak
(Y¼ 0.0597xþ 9.7613; R¼ 0.2556; r2¼ 0.06) relationship
between the LES and STS scores.
Both were poor discriminators of 30-day/in-hospital out-
comes. At 1 year, the discrimination of both STS and LES
scores remained poor with a marginally better performance
for STS score (Table 2).
Both risk scores demonstrated significant differences
between predicted and observed mortalities throughout
the entire range of mortality risk. We found better calibra-
tion of the STSmodel but poor calibration of the LESmodel
for the 30-day outcomes. At 1 year the calibration of STSeons (STS) and logistic European System for Cardiac Operative Risk
cement (n ¼ 2446) Surgical aortic valve replacement (n ¼ 307)
1-year mortality 30-day/in-hospital mortality 1-year mortality
0.56 (0.53-0.58) 0.58 (0.48-0.69) 0.61 (0.54-0.68)
0.56 (0.53-0.59) 0.58 (0.48-0.67) 0.51 (0.44-0.59)
.83 .93 .042
ence interval). STS, Society of Thoracic Surgeons; LES, logistic European System for
diovascular Surgery c Volume 148, Number 6 2833
TABLE 3. Summary of calibration characteristics* of Society of Thoracic Surgeons (STS) and logistic European System for Cardiac Operative
Risk Evaluation (LES) surgical risk scores
Transcatheter aortic valve replacement (n ¼ 2446) Surgical aortic valve replacement (n ¼ 307)
30-day/in-hospital mortality 1-year mortality 30-day/in-hospital mortality 1-year mortality
STS score 0.0016 (0.57) 0.084 (1.03) 0.0322 (1.19) 0.0368 (2.46)
LES score 0.0552 (0.031) 0.1535 (0.18) 0.1602 (0.18) 0.2158 (0.11)
Values are presented as intercept (slope). STS, Society of Thoracic Surgeons; LES, logistic European System for Cardiac Operative Risk Evaluation. *Ideal calibration line:
Y ¼ X, slope ¼ 1, intercept ¼ 0.
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Dscore and LES score was poor (Table 3 and Appendix
Figure E1).
DISCUSSION
The primary findings of our analysis of risk score perfor-
mance in the PARTNER I trial and continued access patients
were the STS and LES surgical risk scores were poorly
correlated and overestimated 30-day/in-hospital mortality
of patients undergoing TAVR, both scores were poor dis-
criminators of 30-day/in-hospital mortality as well as
1-year mortality of patients undergoing TAVR, the calibra-
tion of these scores within the TAVR and SAVR populations
was better for STS score than for LES score, and the calibra-
tion of the STS score was better among the patients under-
going SAVR than those undergoing TAVR at 30 days in
our analysis. Overall, these data highlight the need for
TAVR-specific risk models to optimize patient selection.
The use of the existing surgical risk scores among the
cohort of high-risk patients considered for TAVR is contro-
versial. In part due to the absence of adequate risk stratifica-
tion paradigms, calculation of STS score (or LES score) is
routine in the evaluation of patients undergoing evaluation
for TAVR. In fact, STS predicted risk of mortality was a
key inclusion requirement of the PARTNER trial. Mirroring
this inclusion criterion, the Centers for Medicare and
Medicaid Services have incorporated the STS-predicted
risk of mortality as a benchmark for Medicare TAVR reim-
bursement. STS score and LES score predicted mortality
have thus become an important consideration in the coun-
seling and decision making of patients with AS. As a result,
the outcomes of patients undergoing TAVR have been
compared with STS score and LES score predicted
morbidity and mortality in published literature.11
In the PARTNER experience, both the LES and STS
scores overestimated 30-day/in-hospital TAVR mortality
with observed to expected mortality ratios of 0.15 and
0.57, respectively. The LES and STS scores also overesti-
mated 30-day SAVR mortality with observed to expected
ratios of 0.35 and 0.89, respectively. Additionally, we found
a large discrepancy between the STS and LES scores (both
prospectively calculated) for both the TAVR and SAVR
cohorts. A similar large discrepancy was described by
Piazza et al,11 between LES (prospectively calculated)
and STS (retrospectively calculated) predicted risks of2834 The Journal of Thoracic and Cardiovascular Surmortality when applied to patients undergoing CoreValve
implantation. LES is well known to overestimate mortality
risk among high-risk patients and octogenarians undergoing
SAVR.12-15 The derivation of the LES was based on a
dataset composed chiefly of coronary surgery patients
(approximately 60%), and therefore may be less well
adapted than dedicated valve surgery models for
prediction of operative mortality in patients undergoing
valve surgery.16-23 The LES score was not designed to
predict mortality in patients undergoing isolated SAVR
and has been demonstrated to overestimate mortality in
high-risk patients undergoing SAVR by a factor of 3.8 The
European System for Cardiac Operative Risk Evaluation
II score takes into account that cardiac surgical mortality
has significantly decreased in the past 15 years despite the
inclusion of older and sicker patients as surgical candidates.
This score appears to be well calibrated (actual mortality,
4.18%; predicted mortality, 3.95%) and appeared to have
good overall discriminatory capacity with an AUC of
0.8095 when applied to a traditional risk surgical
population.24 Although the European System for Cardiac
Operative Risk Evaluation II model has replaced the
logistic or additive models, the latter has been extensively
applied to the existing TAVR literature and therefore, while
increasingly of historical importance, the performance
characteristics of this model remain clinically important
to assess. In a recent small study of patients undergoing
TAVR, LES and the STS scores were found to be better
calibrated than the LES but have moderate discrimination
for predicting 30-day mortality after TAVR.25 The applica-
tion of the European System for Cardiac Operative Risk
Evaluation II score to patients undergoing TAVR remains
to be validated. The short-term nature of our study still
leaves in question the durability of the prosthesis and,
therefore, application in patients with more than short- to
intermediate-term life expectancy should be limited until
longer-term experience reveals acceptable performance.
The STS and LES algorithms not only differ in degree of
predicted mortality, but also identify different patients at the
highest risk for SAVR.13 Dewey et al13 previously reported
underestimation of mortality by the STS score (an observed
to expected mortality ratio of 1.41) and overestimation by
the LES score in high-risk patients undergoing SAVR
(observed to expected mortality ratio of 0.31) using thegery c December 2014
FIGURE 2. Patients undergoing transcatheter aortic valve replacement. A, Calibration plots of the Society of Thoracic Surgeons (STS) scores for 30-day/
in-hospital mortality. Perfect calibration is represented by the dashed line whereby observed equals predicted probability of mortality (X ¼ Y, slope ¼ 1,
intercept ¼ 0). B, Calibration plots of the logistic European System for Cardiac Operative Risk Evaluation (LES) score for 30-day/in-hospital mortality.
Perfect calibration is represented by the dashed linewhereby observed equals predicted probability of mortality (X¼ Y, slope¼ 1, intercept ¼ 0). C, Cali-
bration plots of the STS scores for 30-day/in-hospital morality analyzed by tertiles. Perfect calibration is represented by the dashed line whereby observed
equals predicted probability of mortality (X¼ Y, slope¼ 1, intercept¼ 0). D, Calibration plots of the LES scores for 30-day/in-hospital mortality analyzed
by tertiles. Perfect calibration is represented by the dashed linewhereby observed equals predicted probability of mortality (X¼Y, slope¼ 1, intercept¼ 0).
E, Calibration plots for the STS scores for 1-year mortality. Perfect calibration is represented by the dashed line whereby observed equals predicted prob-
ability of mortality (X ¼ Y, slope ¼ 1, intercept¼ 0). F, Calibration plots for the LES for 1-year mortality. Perfect calibration is represented by the dashed
line whereby observed equals predicted probability of mortality (X ¼ Y, slope ¼ 1, intercept ¼ 0).
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DLES score, among 64 high-risk aortic valve replacement pa-
tients. A general shortcoming of all surgical risk algorithms,
including the STS and LES scores, is the omission of
several measurable and immeasurable risk factors known
to influence patient selection and mortality.7,16-19,26 For
example, both models fail to include porcelain aorta,
mediastinal radiation, malnutrition, and patient frailty.
This should in theory result in an underestimation of
mortality, but in our analysis both risk models in fact
overestimated mortality.
To guide patient selection, prognostic models must have
good discrimination (ie, ability to correctly classify
patients as dead or alive) and calibration (ie, comparison
between observed and predicted mortality) not only at
short-term follow-up but also at longer-term follow-up.27
This is especially true in patients undergoing TAVR
where a substantial residual mortality remains following
successful TAVR.3,4 We found suboptimal discriminatory
power of both the STS and LES risk scores for both
periprocedural and 1-year mortality among both TF and
TA cohorts. For the SAVR population, STS performed
poorly and similar to the LES in the short term but
performed better than LES at 1 year. The calibration
was good for the STS score but poor for the LES score
for patients undergoing both TF and TA TAVR as well
as for patients undergoing SAVR at both 30-day and
1-year follow-up. In a previous analysis of patients under-
going TAVR using the CoreValve device, the STS score
outperformed the LES score, but both LES and STS score
had suboptimal discriminatory power and calibration.11
A recently published smaller study of patients undergoing
TAVR (n ¼ 250) found that the STS score is better cali-
brated than the LES score but has moderate discrimination
for predicting 30-day mortality after TAVR.25 This lack of
discrimination and calibration is not surprising given the
extrapolation of surgical risk scores to a high-risk popula-
tion of TAVR patients underrepresented in the derivation
and/or validation datasets from which these scores were
derived. This accounts for some of the overestimation of
risk seen with many models. Additionally, the risk scores
cannot account for the risk of random events and their ef-
fect on outcomes, such as operator error during TAVR.
Furthermore, given that both surgical risk scores greatly
overestimate the actual mortality of patients undergoing
TAVR, complacency may arise when these are used as
benchmarks of performance. Consistent with our findings,
the recently published European Society of Cardiology/
European Association for Cardiothoracic Surgery 2012
guidelines point out the lack of accuracy of the STS and
LES scores and recommend the development of dedicated
risk scores for transcatheter heart valve interventions and
in the interim recommend the evaluation and prognostica-
tion of patients by a dedicated heart team.282836 The Journal of Thoracic and Cardiovascular SurLimitations
Our analysis presents a secondary analysis of the data
collected as part of the PARTNER I randomized controlled
trial and continued access registries and therefore should be
considered hypothesis-generating. The analyzed patient
population was part of the initial North American TAVR
experience and the risk profile may not be representative
of current high-risk profile patients being screened for
TAVR. A larger sample size may better guide the develop-
ment of an optimal TAVR-specific risk score. Although it
would be of interest to determine the performance charac-
teristics of the European System for Cardiac Operative
Risk Evaluation II score as applied to the PARTNER data-
set, this was not feasible because both STS and LES scores
were calculated prospectively at the site level during the
screening process when patient eligibility was determined.
The calculated scores were then entered into the PARTNER
case report form. As such, the individual components
contributing to the calculation of each risk score were not
systematically captured as part of the case report form.
Therefore, several variables used by the European System
for Cardiac Operative Risk Evaluation II algorithm (http://
euroscore.org/calc.html) are not directly available in the
PARTNER database. Rather than perform multiple imputa-
tions to derive approximated versions of these variables in
each patient (which would introduce significant inaccu-
racy), we chose not to perform these analyses recognizing
the inherent limitations in such an approach.
CONCLUSIONS
Existing surgical risk scores are weakly correlated and
poor discriminators of 30 day/in-hospital and 1-year out-
comes of TAVR and high-risk SAVR, but exhibit some de-
gree of calibration to these outcomes (specifically STS
score). Validated TAVR-specific risk models need to be
developed to optimize patient selection and improve clin-
ical outcomes. Until such validated TAVR-specific risk
scores are available, clinical judgment integrating input
from a heart team should guide clinical decision making.
Additionally, recalibration of the risk scores, especially
LES score, may be warranted to better predict outcomes
of high-risk patients undergoing SAVR.
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APPENDIX FIGURE E1. Patients undergoing surgical aortic valve replacement. A, Calibration plots for the Society of Thoracic Surgeons (STS) scores
for 30-day/in-hospital mortality. Perfect calibration is represented by the dashed line whereby observed equals predicted probability of mortality (X ¼ Y,
slope ¼ 1, intercept ¼ 0). B, Calibration plots for the logistic European System for Cardiac Operative Risk Evaluation (LES) score for 30-day/in-hospital
mortality. Perfect calibration is represented by the dashed linewhereby observed equals predicted probability of mortality (X¼Y, slope¼ 1, intercept¼ 0).
C, Calibration plots for the STS scores for 1-year mortality. Perfect calibration is represented by the dashed line whereby observed equals predicted prob-
ability of mortality (X¼ Y, slope¼ 1, intercept¼ 0). D, Calibration plots for LES for 1-year mortality. Perfect calibration is represented by the dashed line
whereby observed equals predicted probability of mortality (X ¼ Y, slope ¼ 1, intercept ¼ 0).
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